Andoh T, Okada K
Meiji College of Pharmacy, Division of Blood Transfusion, Hiroshima University Hospital.
Gan To Kagaku Ryoho. 1989 Mar;16(3 Pt 2):569-75.
Since the discovery of several potent anticancer agents which are specific inhibitors of DNA topoisomerases, the key enzymes in the DNA metabolism, efforts to elucidate the mechanism of acquired resistance to these agents and to overcome them have been focused on these enzymes, the cellular targets of the anticancer agents. These trends were briefly reviewed.
自从发现了几种有效的抗癌药物,它们是DNA拓扑异构酶(DNA代谢中的关键酶)的特异性抑制剂以来,阐明对这些药物获得性耐药机制并克服耐药性的努力一直集中在这些酶上,即抗癌药物的细胞靶点。本文简要回顾了这些研究趋势。